Naltrexone during pain conditioning: A double-blind placebo-controlled experimental trial
نویسندگان
چکیده
منابع مشابه
A double-blind, placebo-controlled trial
not all patients underwent regular follow-up endoscopy .after apparent healing. In adults it is now well known that many relapses are entirely asymptomatic and it is possible that the same applies in children. After initial diagnosis and treatment, no patient subsequently presented with complications of gastro-intestinal bleeding or perforation. It would seem that the consequences of missing an...
متن کاملA Randomized, Double-Blind, Placebo-Controlled Trial
Results: The cumulative number of gadoliniumenhancing MRI lesions during the first 6 months were similar in the -3 fatty acids and placebo groups (median difference, 1; 95% CI, 0 to 3; P=.09). No difference in relapse rate was detected after 6 (median difference, 0; 95% CI, 0 to 0; P=.54) or 24 (median difference, 0; 95% CI, 0 to 0; P=.72) months. The proportion of patients without disability p...
متن کاملA Randomized, Placebo-Controlled Double-Blind Trial
The efficacy and safety of pentoxifylline were assessed in 297 adult patients with ischemic stroke in a molticenter, doable-blind, randomized and placebo-controlled trial. Treatment was started within 12 hoars after the stroke onset Study medication was administered intravenously continuously (16 mg/kg/day, maximum 1,200 mg/day) for 3 days and per os (400 mg ti.d.) for the remainder of 28 days....
متن کاملA Randomized, Double-Blind, placebo-Controlled Trial
Method: Five hundred forty-two outpatients with bipolar I (N=360) or 11 (N=182) disorder experiencing a major depressive episode (DSM-IV) were randomly assigned to 8 weeks of quetiapine (600 or 300 mgl day) or placebo. The prima ry efficacy measure was mean change from base))ne to week 8 in the Montgomery-Asberg Depression Rating Scale total score. Additional efficacy assessments included the H...
متن کامل[Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
UNLABELLED We aimed to assess the efficacy and safety of an injectable, once monthly extended-release formulation of the opioid antagonist naltrexone (XR-NTX) for treatment of patients with opioid dependence after detoxification. Two hundreds and fifty patients with opioid dependence were enrolled into the double-blind, placebo-controlled, randomized, 24-week trial. Patients aged 18 years or ov...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecular Pain
سال: 2020
ISSN: 1744-8069,1744-8069
DOI: 10.1177/1744806920927625